|
A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. avium Complex (MAC) Infections in Patients With AIDS Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. avium Complex (MAC) Infections in Patients With AIDS conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. avium Complex (MAC) Infections in Patients With AIDS Clinical research trials and A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. avium Complex (MAC) Infections in Patients With AIDS health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. avium Complex (MAC) Infections in Patients With AIDS. A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. avium Complex (MAC) Infections in Patients With AIDS Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. avium Complex (MAC) Infections in Patients With AIDS clinical trial. Participants oftentimes recieve the most expert healthcare available for their A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. avium Complex (MAC) Infections in Patients With AIDS condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. avium Complex (MAC) Infections in Patients With AIDS  A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. avium Complex (MAC) Infections in Patients With AIDS
A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. avium Complex (MAC) Infections in Patients With AIDS
For Condition: Mycobacterium avium-intracellulare Infection,HIV Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) , Abbott Laboratories
Synopsis: This study is designed to evaluate the efficacy and safety of clarithromycin given orally at 1 of 3 doses to treat disseminated Mycobacterium avium complex infections (MAC) in patients with AIDS. Mycobacterium avium complex (MAC) is thought to be the most common disseminated bacterial opportunistic infection in AIDS, with clinical prevalence estimates ranging from 15 to 50 percent of all AIDS patients. Clarithromycin, a new macrolide antimicrobial agent, has demonstrated activity against MAC both in the laboratory and in animals. Clinical experience treating AIDS patients with clarithromycin for disseminated MAC is limited. However, early studies have indicated few adverse effects and some improvement in clinical symptoms scores and Karnofsky performance scores over placebo treated patients.
Details: Mycobacterium avium complex (MAC) is thought to be the most common disseminated bacterial opportunistic infection in AIDS, with clinical prevalence estimates ranging from 15 to 50 percent of all AIDS patients. Clarithromycin, a new macrolide antimicrobial agent, has demonstrated activity against MAC both in the laboratory and in animals. Clinical experience treating AIDS patients with clarithromycin for disseminated MAC is limited. However, early studies have indicated few adverse effects and some improvement in clinical symptoms scores and Karnofsky performance scores over placebo treated patients. Treatment is randomly assigned so that twice as many patients receive clarithromycin at the lower dose as at an intermediate dose for 12 weeks. Once data becomes available to support dosing patients with clarithromycin at the highest dose, then treatment will be randomly assigned so that twice as many patients receive clarithromycin at the highest dose as at the intermediate dose. Sixteen patients per group (48 patients in all) will be enrolled. Patients exhibiting clinical improvement or clinical cure while on this trial will be allowed to continue on therapy for an additional 6 months. Patients will have clinical evaluations (including the Karnofsky Performance Scale), laboratory evaluations (hematology and chemistry), and blood cultures for MAC performed monthly.
Eligibility:
Study Type: Interventional, Treatment, Double-Blind
Minimum Age/Maximum Age: 13 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Didanosine (ddI). - Dideoxycytidine (ddC). - Zidovudine (AZT). - Acetaminophen. - Acyclovir. - Fluconazole. - Erythropoietin (EPO). - Systemic Pneumocystis carinii pneumonia (PCP) prophylaxis (aerosolized or oral pentamidine, trimethoprim / sulfamethoxazole, or dapsone). - Maintenance ganciclovir therapy (permitted only if dose and clinical and laboratory parameters have been stable for at least 4 weeks prior to study entry). - Maintenance treatment for other opportunistic infections if the dose and clinical and laboratory parameters have been stable for 4 weeks prior to study entry. Patients must have: - Positive results for HIV by ELISA confirmed by another method. - Positive blood culture for Mycobacterium avium complex within 2 months of study entry and clinical symptoms of MAC infection. - Discontinued all mycobacterial drugs (approved and investigational) for at least 4 weeks prior to the start of drug therapy (with the exception of isoniazid prophylaxis which should be discontinued at Study Day minus 14 to Study Day minus 7 - Given written informed consent to participate in the trial. - Met the listed laboratory parameters in the pre-treatment visit. Prior Medication: Allowed: - Didanosine (ddI). - Deoxycytidine (ddC). - Zidovudine (AZT). - Acetaminophen. - Acyclovir. - Fluconazole. - Erythropoietin (EPO). - Systemic Pneumocystis carinii pneumonia (PCP) prophylaxis (aerosolized or oral pentamidine, dapsone, trimethoprim / sulfamethoxazole). - Maintenance ganciclovir therapy (permitted only if dose and clinical and laboratory parameters have been stable for at least 4 weeks prior to study entry). Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Active opportunistic infections. Maintenance treatment for other opportunistic infections will be permitted if the dose and clinical and laboratory parameters have been stable for 4 weeks prior to study entry. Concurrent Medication: Excluded: - Aminoglycosides. - Ansamycin (rifabutin). - Quinolones. - Other macrolides. - Clofazimine. - Cytotoxic chemotherapy. - Rifampin. - Ethambutol. - Immunomodulators (except alpha interferon). - Investigational drugs (except ddI, ddC, and erythropoietin). Patients with the following are excluded: - History of allergy to macrolide antimicrobials. - Currently on active therapy with any anti-mycobacterial drugs listed in Exclusion Prior Medications. - Currently on active therapy with carbamazepine or theophylline, unless the investigator agrees to carefully monitor blood levels. - Inability to comply with the protocol or judged to be near imminent death by the investigator. - Active opportunistic infections. - Requiring any of the excluded concomitant medications. Prior Medication: Excluded for at least 4 weeks prior to study entry: - All anti-mycobacterial drugs (approved and investigational) with the exception of isoniazid prophylaxis, which should be discontinued at Study Day minus 14 to minus 7.
Total Enrollment: 100
Location and Contact Information:
Overall Study Official:
ChaissonR, Study Chair,
Johns Hopkins Hosp
Baltimore, Maryland, 21287
United States
Univ of Southern California / LA County USC Med Ctr
Los Angeles, California, 900331079
United States
Rush Presbyterian - Saint Luke's Med Ctr
Chicago, Illinois, 60612
United States
Additional Information:
Study ID Numbers: ACTG 157;
Study Start Date:
Record last reviewed: October 1994
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000644
Other Mycobacterium Avium-Intracellulare Infection Studies:
1. The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV Drugs
2. The Safety and Effectiveness of Zidovudine (AZT) in the Treatment of HIV Infection in Patients with AIDS and Advanced ARC
3. A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.
4. A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex
5. The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients
Related Studies:
Other Mycobacterium avium-intracellulare Infection Clinical Trials
Other Illinois Clinical Trials
Other Chicago Clinical Trials
A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. avium Complex (MAC) Infections in Patients With AIDS
|
|
|
|
|
|
|
|
